Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough ...

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline by ...